MARKET

ADPT

ADPT

Adaptive Biotechnologies
NASDAQ

Real-time Quotes | Nasdaq Last Sale

45.83
-0.57
-1.23%
After Hours: 45.83 0 0.00% 16:41 11/23 EST
OPEN
46.72
PREV CLOSE
46.40
HIGH
47.04
LOW
44.69
VOLUME
552.08K
TURNOVER
--
52 WEEK HIGH
54.20
52 WEEK LOW
15.19
MARKET CAP
6.27B
P/E (TTM)
-48.2320
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients
GlobeNewswire · 14h ago
Preliminary Data from Real-World Study Demonstrate T-cell Testing Outperforms Antibody Testing in Identifying Past SARS-CoV-2 Infections
– Findings support upcoming launch of T-Detect™ COVID, first T-cell test for novel coronavirus – Data support mounting evidence that measuring T-cells is necessary to fully characterize immune responses to SARS-CoV-2 across the population – Additional supporting data to be published soonSEATTLE, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its T-Detect™ Assay for past SARS-CoV-2 infection in development identified 97% (68/70) of past PCR-confirmed SARS-CoV-2 infections compared to 77% (54/70) with commercial EUA approved antibody testing at similar specificity approximately two months after PCR diagnosis. Additionally, the T-cell response was greater in symptomatic versus asymptomatic subjects, whereas there was no correlation between antibody levels and disease severity in recovered patients. Preliminary results of this study, performed in collaboration with University of Padua and Ospedale San Raffaele in Milan, who were funded by a grant from Umberto Veronesi Foundation were made available on medRxiv. T-Detect™ COVID will be launched later this fall, becoming the first clinical T-cell based diagnostic test able to confirm past infections to SARS-CoV-2.It is likely that some people may never develop antibodies to SARS-CoV-2 because they can resolve the infection early and effectively with T cells. Recent studies have demonstrated that antibodies appear to wane over time¹, while virus-specific T cells have been shown to persist for at least six months². This new study adds to mounting evidence that T cells, along with antibodies, may serve as an important correlate of immune protection and can help provide a more complete picture of the duration of immunity to the virus following an infection or administration of a vaccine.“These data add to the growing body of real-world evidence that the T cell plays a critical role in immunity to SARS-CoV-2,” said Lance Baldo, Chief Medical Officer of Adaptive Biotechnologies. “T cells are emerging as another key indicator for past infection and immunity to the novel coronavirus, and a T-cell test for patients that is accurate and reproducible can serve large populations of people given what we are learning about the biology of the immune response.”An initial study published in Nature in June 2020 was conducted by the University of Padua in which nearly the entire population of Vo’, Italy (2,900 of the town’s 3,275 residents), was tested using PCR for SARS-CoV-2 infection at the beginning and end of a 14-day lockdown of the town, followed by longer-term clinical monitoring. At that time, 81 people in the town tested positive for the virus in at least one of the two surveys. Interestingly, more than 40% of those who tested positive were asymptomatic, guiding the town’s response to the then-emerging pandemic and driving their success in containment³.In a follow-up study of 2,290 residents, including 70 of the 81 who tested positive by PCR, antibody testing with a EUA approved commercial test (IgG) and T-cell testing with Adaptive’s T-Detect Assay for past SARS-CoV-2 infection were performed approximately 60 days after PCR testing. The T-cell assay identified 97% (68/70) of past PCR-confirmed SARS-CoV-2 infections compared to 77% (54/70) with the antibody test. Notably, 24 of the 70 PCR -positive patients were asymptomatic, highlighting the added sensitivity of T-cell based testing to provide a more accurate representation of past infection in a community. The T-cell response was measured by the overall quantity of T cells as well as the number of unique virus-specific T cells. Convalescent subjects who were symptomatic and hospitalized with COVID-19 had significantly greater T-cell response than asymptomatic subjects, while antibody levels did not correlate with disease severity.Notably, an additional 45 (2.0%) of PCR-negative participants tested positive with the T-Detect Assay for past SARS-CoV-2 infection. About half of these individuals had reported symptoms before or after PCR testing or a household exposure, indicating the T-cell assay may also identify past infections that had been missed by prior PCR testing.About T-Detect™ T-Detect™ is a highly sensitive and specific diagnostic test under development for multiple diseases, translating the natural diagnostic capability of T cells into clinical practice. In 2018, Adaptive and Microsoft partnered to build a map of the immune system called the TCR-Antigen Map. This approach uses immunosequencing, proprietary computational modeling, and machine learning to map T-cell receptor sequences to disease-associated antigens for infectious diseases, autoimmune disorders and cancer. From a simple blood draw, T-Detect will leverage the map to provide an immunostatus for an individual, enabling early disease diagnosis, disease monitoring, and critical insights into immunity. T-Detect COVID will be the first clinical test launched from this collaboration and the first commercially available T cell test designed to detect past SARS-CoV-2 infections. It is expected to launch this fall.About Adaptive Biotechnologies Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have two commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com and follow us on www.twitter.com/adaptivebiotech.Forward Looking StatementsThis press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements.These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including statements regarding T-Detect™ and its launch, potential commercial acceptance, or clinical utility, either with respect to COVID-19 or other disease states. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time, including a Quarterly Report on Form 10-Q to be filed later today. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.ADAPTIVE MEDIA Beth Keshishian 917-912-7195 media@adaptivebiotech.comADAPTIVE INVESTORS Karina Calzadilla, Vice President, Investor Relations 201-396-1687 Carrie Mendivil, Gilmartin Group investors@adaptivebiotech.com___________________________________ ¹ Ward, et al.medRxiV preprint, 2020  ² Zuo, et al. bioRxiV preprint, 2020 ³ Lavezzo, et al. Nature, 2020​
GlobeNewswire · 11/13 13:00
Does Adaptive Biotechnologies' (NASDAQ:ADPT) Share Price Gain of 66% Match Its Business Performance?
If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly...
Simply Wall St. · 11/11 10:21
Adaptive Biotechnologies Announces Collaboration with GSK to Measure Minimal Residual Disease with clonoSEQ® Assay Across its Hematology and Oncology Portfolio
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a collaboration with GlaxoSmithKline plc (GSK) to use its clonoSEQ® Assay to assess minimal residual disease (MRD) in GSK’s portfolio of hematology products. “We are thrilled to collaborate with GSK to implement our leading MRD test across their groundbreaking hematology portfolio as a measure of treatment response and patient outcomes,” said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. “MRD is increasingly used as an endpoint in clinical trials, and clonoSEQ has emerged as the premier test to reliably and accurately measure MRD to help advance novel therapies.”In hematologic malignancies, MRD testing can be used to see if a patient is responding to treatment or if the cancer has come back. It is performed as a series of tests throughout a patient’s cancer journey. The clonoSEQ Assay is the first and only next-generation sequencing (NGS)-based MRD test authorized by the FDA to detect and monitor MRD in multiple myeloma, chronic lymphocytic leukemia and B-cell acute lymphoblastic leukemia.As part of the non-exclusive, pan-portfolio translational collaboration, Adaptive’s clonoSEQ Assay also may be used in GSK hematology clinical trials to generate data supporting the clinical value of monitoring MRD in the context of patient care.Adaptive will receive upfront and potential future regulatory milestone payments in certain geographies. Specific financial terms of the agreement will not be disclosed.About the clonoSEQ Assay The clonoSEQ Assay is the first and only FDA-cleared assay for MRD in chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL). Minimal residual disease (MRD) refers to the small number of cancer cells that can stay in the body during and after treatment. clonoSEQ was initially granted De Novo designation and marketing authorization by the FDA for the detection and monitoring of MRD in patients with MM and B-ALL using DNA from bone marrow samples. In August 2020, clonoSEQ received additional clearance from the FDA to detect and monitor MRD in blood or bone marrow from patients with CLL. The clonoSEQ Assay leverages Adaptive’s proprietary immune medicine platform to identify and quantify specific DNA sequences found in malignant cells, allowing clinicians to assess and monitor MRD during and after treatment. The assay provides standardized, accurate and sensitive measurement of MRD that allows physicians to predict patient outcomes, assess response to therapy over time, monitor patients during remission and predict potential relapse. Clinical practice guidelines in hematological malignancies recognize that MRD status is a reliable indicator of clinical outcomes and response to therapy, and clinical outcomes have been shown to be strongly associated with MRD levels measured by the clonoSEQ Assay in patients diagnosed with CLL, MM and ALL. The clonoSEQ Assay is a single-site test performed at Adaptive Biotechnologies. In addition to its FDA-cleared uses, clonoSEQ is also available as a CLIA-validated laboratory developed test (LDT) service for use in other lymphoid cancers and sample types.  For important information about the FDA-cleared uses of clonoSEQ, including the full intended use, limitations, and detailed performance characteristics, please visit www.clonoSEQ.com/technical-summary.About Adaptive Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com and follow us on www.twitter.com/adaptivebiotech.Forward Looking Statements This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.ADAPTIVE MEDIA Beth Keshishian 917-912-7195 media@adaptivebiotech.comADAPTIVE INVESTORS Karina Calzadilla, Vice President, Investor Relations 201-396-1687 Carrie Mendivil, Gilmartin Group investors@adaptivebiotech.com
GlobeNewswire · 11/10 21:13
Earnings Preview: Adaptive Biotechnologies (ADPT) Q3 Earnings Expected to Decline
Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 11/03 17:30
Amgen Earnings, Sales Top Wall Street Views; Hikes Earnings Guidance
Investor's Business Daily · 10/28 21:39
Do Hedge Funds Love Adaptive Biotechnologies Corporation (ADPT)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
Insider Monkey · 09/28 15:52
Lilly and Amgen partner to manufacture potential coronavirus drugs
Eli Lilly has partnered with Amgen to increase the capacity of its experimental C-19 antibody treatment, a day after one of the drug was shown to reduce the need for hospitalization.
Reuters · 09/17 11:17
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADPT. Analyze the recent business situations of Adaptive Biotechnologies through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADPT stock price target is 58.17 with a high estimate of 66.00 and a low estimate of 46.00.
EPS
Institutional Holdings
Institutions: 284
Institutional Holdings: 110.96M
% Owned: 81.13%
Shares Outstanding: 136.77M
TypeInstitutionsShares
Increased
94
11.39M
New
65
1.78M
Decreased
42
3.64M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Executive Director
Chad Robins
President
Julie Rubinstein
Co-Founder/Chief Scientific Officer
Harlan Robins
Chief Financial Officer
Chad Cohen
Senior Vice President/General Manager
.. Willis
Chief Human Resource Officer
Francis Lo
Senior Vice President/General Counsel
Stacy Taylor
Senior Vice President
Sharon Benzeno
Senior Vice President
Nancy Hill
Senior Vice President
Jyoti Palaniappan
Senior Vice President
Charles Snag
Chief Technology Officer
Mark Adams
Other
Lance Baldo
Other
Sean Nolan
Lead Director/Independent Director
Peter Neupert
Independent Director
Kevin Conroy
Independent Director
Eric Dobmeier
Independent Director
David Goel
Independent Director
Michelle Griffin
Independent Director
Robert Hershberg
Independent Director
Michael Pellini
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ADPT
Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). clonoSEQ is its diagnostic test product for the detection and next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in bone marrow samples in patients with myeloma (MM) and acute lymphoblastic leukemia (ALL). clonoSEQ is designed to sequence all rearranged receptor sequences in a tumor in parallel to enable MRD monitoring. It also focuses on developing immune-mediated therapies in oncology and other disease areas.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Adaptive Biotechnologies Corp stock information, including NASDAQ:ADPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADPT stock methods without spending real money on the virtual paper trading platform.